##  [ICH E17-GL: General Principles for Planning and Design of Multi-Regional Clinical Trials](/blog/ich-e17-gl-general-principles-for-planning-and-design-of-multi-regional-clinical-trials) 

    August 29, 2025 

  ![ich-e17-gl-general-principles-for-planning-and-design-of-multi-regional-clinical-trials]()

2 min read 

- [Medicinal Products](/blog-main-categories/medicinal-products)
- [Regulatory Affairs](/blog-main-categories/regulatory-affairs)





 

In today’s global pharmaceutical landscape, **multi-regional clinical trials (MRCTs)** have become a cornerstone of efficient drug development. By enrolling patients across multiple geographic regions in a single trial, sponsors can accelerate development timelines, reduce redundancy, and meet regulatory requirements in multiple markets simultaneously.

The **ICH E17 guideline**, “General Principles for Planning and Design of Multi-Regional Clinical Trials,” provides a harmonized framework for designing MRCTs that generate robust, regionally relevant evidence for regulatory submissions. For companies aiming to include Japan in their MRCT strategy, understanding and applying ICH E17-GL is critical — both for scientific validity and for meeting **PMDA expectations**.

## Purpose of ICH E17-GL

ICH E17-GL was developed to:

- **Harmonize MRCT planning** across ICH member regions.
- Enable **simultaneous drug development** that satisfies multiple regulatory authorities.
- Support **extrapolation of results** across regions without unnecessary duplication of trials.
- Ensure **diverse population representation**, addressing potential ethnic or regional differences in drug response.

## Core Principles for MRCT Planning

The guideline outlines several key elements for successful MRCT design:

1. **Early and Inclusive Planning** – Regional input should be sought early to align on trial objectives, endpoints, and operational considerations.
2. **Appropriate Sample Size Allocation** – Ensure enough patients are enrolled in each region, including Japan, to support **bridging** and **comparability assessments**.
3. **Consideration of Ethnic Factors** – Integrate ICH E5 guidance on intrinsic (genetic, physiological) and extrinsic (diet, healthcare systems) factors affecting drug response.
4. **Consistent Study Conduct** – Harmonize protocols, procedures, and data collection across sites to ensure scientific validity.
5. **Regulatory Engagement** – Maintain dialogue with authorities like the **PMDA** throughout trial planning to avoid surprises at submission.

## ICH E17 and Japan’s PMDA

Japan’s PMDA actively encourages inclusion of Japanese patients in MRCTs to avoid the need for separate bridging studies. However, the PMDA expects careful **sample size planning**, robust **statistical justification** for pooling data, and a clear demonstration of **data consistency across regions**.

Sponsors that fail to meet these expectations risk **delayed approvals** or requests for additional local trials.

## How Freyr Solutions Supports MRCT Success

At **Freyr Solutions**, we help global sponsors design MRCTs that meet **ICH E17-GL principles** while aligning with **Japan-specific regulatory needs**. Our **Japan-based bilingual experts** work closely with global teams to:

- Provide **early regulatory intelligence** from the PMDA.
- Conduct **feasibility assessments** for Japanese patient recruitment.
- Optimize **sample size allocation** for Japanese inclusion.
- Support **end-to-end MRCT documentation and submissions**.

By combining **global regulatory expertise** with **deep local insight**, Freyr ensures MRCTs generate data that is both scientifically robust and regionally compliant — accelerating approvals and avoiding costly delays.

## Conclusion

ICH E17-GL offers a powerful framework for designing MRCTs that serve multiple markets efficiently. For companies targeting Japan, incorporating PMDA requirements from the outset is essential. With **Freyr Solutions** as your strategic partner, you gain access to **local Japanese expertise**, global experience, and a proven methodology for turning ICH E17 principles into regulatory success.

**Freyr Solutions — bridging global trial design with local regulatory excellence in Japan.**